Adaptin Begins Patient Enrollment In Phase 1 Trial Of APTN-101 For Glioblastoma
(RTTNews) - Adaptin Bio, Inc. (APTN), a biotech company focused on developing precision cancer therapeutics, announced the initiation of enrollment in a Phase 1 trial evaluating APTN-101 for the treatment of glioblastoma.
(RTTNews) - Adaptin Bio, Inc. (APTN), a biotech company focused on developing precision cancer therapeutics, announced the initiation of enrollment in a Phase 1 trial evaluating APTN-101 for the treatment of glioblastoma.